Browse All

Current Filters

CLEAR FILTER x

TITLE

Blood Biomarker Dynamics in Highly Active Relapsing Multiple Sclerosis Patients Treated With Cladribine Tablets: Results of the 2-Year MAGNIFY-MS Study

Author:Wiendl, Heinz   De Stefano, Nicola   Barkhof, Frederik   Montalban, Xavier   Achiron, Anat   Derfuss, Tobias   Chan, Andrew   Hodgkinson, Suzanne   Prat, Alexandre   Leocani, Letizia   Schmierer, Klaus   Sellebjerg, Finn   Vermersch, Patrick   Jin, Hulin   Jarvinen, Elina   Chudecka, Anita   Gardner, Lidia   

Session Name:S16: MS Clinical Trials and Therapeutics  

Topic:MS and Inflammatory Disease  

Program Number:S16.006  

Author Institution:University of Muenster, Muenster, Germany  Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy  VU University Medical Center, Amsterdam, Netherlands  Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitario Vall d’Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain  Multiple Sclerosis Center, Sheba Academic Medical Center, Ramat Gan, Israel  University Hospital Basel, Basel, Switzerland  Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland  Ingham Institute for Applied Medical Research, University of New South Wales Medicine, Sydney, Australia  Université de Montréal, Montreal, QC, Canada  Experimental Neurophysiology Unit, Vita-Salute San Raffaele University, Milan, Italy  The Blizard Institute, Centre for Neuroscience, Surgery & Trauma, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, London, United Kingdom  Copenhagen University Hospital - Rigshospitalet, Glostrup, Denmark  Inserm U1172 LilNCog, CHU Lille, FHU Precise, Lille, France  the healthcare business of Merck KGaA, Darmstadt, Germany, Darmstadt, Germany  Cytel Inc. Geneva, Switzerland, Geneva, Switzerland  EMD Serono, Billerica, MA, USA, Billerica, MA  

NfL as a Predictor of GdE Lesions in Patients With Relapsing Multiple Sclerosis Treated With Ozanimod in the Phase 2 RADIANCE Trial

Early Onset of Action and Sustained Efficacy of MRI Outcomes During Cladribine Tablets Treatment in Highly Active Relapsing Multiple Sclerosis: Results of the 2-year MAGNIFY-MS Study

Author:De Stefano, Nicola   Achiron, Anat   Barkhof, Frederik   Chan, Andrew   Derfuss, Tobias   Hodgkinson, Suzanne   Leocani, Letizia   Montalban, Xavier   Prat, Alexandre   Schmierer, Klaus   Sellebjerg, Finn   Vermersch, Patrick   Wiendl, Heinz   Keller, Birgit   Smyk, Andrzej   Gardner, Lidia   

Session Name:P6: MS Clinical Trials  

Topic:MS and Inflammatory Disease  

Program Number:P6.018  

Author Institution:Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy  Multiple Sclerosis Center, Sheba Academic Medical Center, Ramat Gan, Israel  Department of Radiology, VU University Medical Center, Amsterdam, Netherlands  Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland  Department of Neurology, University Hospital Basel, Basel, Switzerland  Ingham Institute for Applied Medical Research, University of New South Wales Medicine, Sydney, Australia  Experimental Neurophysiology Unit, Vita-Salute San Raffaele University, Milan, Italy  Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitario Vall d’Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain  Department of Neurosciences, Université de Montréal, Montreal, QC, Canada  The Blizard Institute, Centre for Neuroscience, Surgery & Trauma, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, London, United Kingdom  Danish MS Center, Department of Neurology, Copenhagen University Hospital - Rigshospitalet, Glostrup, Denmark  Univ. Lille, Inserm U1172 LilNCog, CHU Lille, FHU Precise, Lille, France  Department of Neurology, Institute of Translational Neurology, University of Münster, Muenster, Germany  the healthcare business of Merck KGaA, Darmstadt, Germany, Darmstadt, Germany  EMD Serono Research and Development Institute, Inc., Billerica, MA, USA , Billerica, MA